Replies to post #30227 on Humanigen Inc (fka HGENQ)

[fintradingt]

Not so fast. LIVE-AIR (the Ph3 trial) was Lenzilumab + SOC (remdesivir and/or dexamethasone) vs placebo + SOC. ACTIV-5 is Lenz + remdesivir vs placebo + remdesivir. The two trials have similarities. If anything, LIVE-AIR was a superset of ACTIV-5, with dex being left out of the latter. ACTIV-5 may keep running so that they can gather more data on Lenz + remdesivir specifically (if I remember correctly, in the LIVE-AIR results, Lenz + remdesivir and dex was not significantly better than Lenz + remdesivir alone), but I think there's something to the point Don brought up.